CVKD — Q2 2026 Financial Report Analysis

Cadrenal Therapeutics, a drug developer with no product on the market and therefore no sales, lost $3.3 million in the second quarter of 2026, 9% less than the $3.7 million it lost a year earlier. The smaller loss came almost entirely from research spending, which fell 35% to $0.7 million because the company is paying far less for drug manufacturing work. That cut is not a sign of a program winding down on schedule: the company now says it will not run its own late-stage (Phase 3) trials at all, and is instead trying to license or partner its three heart-and-blood-clot drug candidates. It ended June with $2.4 million of cash, and management says cash on hand in early August ($4.2 million, after a July share sale) lasts only through the first quarter of 2027.

At a glance

• $2.4 million cash at June 30, 2026, down from $4.0 million at the start of the year, against $5.2 million spent running the business in the first half. The company itself says there is "substantial doubt" it can keep operating for another year without new money.
• Research spending fell 35% to $0.7 million in the quarter, driven by a $0.7 million drop in chemistry, manufacturing and controls (CMC, the work of making and testing batches of the drug). Overhead (general and administrative costs) stayed at $2.6 million and is now nearly four times research spending.
• Loss per share improved to -$1.14 from -$1.87, but mostly because there are more shares: the average share count rose 49% to 2.91 million, from 1.96 million, after repeated stock and warrant sales.

The quarter in numbers

For the first half of 2026, the net loss was $5.8 million versus $7.5 million a year earlier (23% smaller). Research spending fell 46% to $1.5 million and overhead fell 11% to $4.4 million.

Why spending fell, and what it says about strategy

The filing explains the research decline directly: in the quarter, a $0.7 million drop in CMC costs and a $0.2 million drop in consulting and professional fees. For the half-year, CMC fell $1.2 million, stock-based pay in research fell $0.3 million and staff costs fell $0.2 million, partly offset by $0.5 million more spent on consultants.

The reason behind the lower manufacturing bill is a change in plan. After its End-of-Phase 2 meeting with the FDA, the company sized the pivotal trial the agency wants for its lead drug, CAD-1005 (a 120-patient, placebo-controlled study in heparin-induced thrombocytopenia, or HIT, a dangerous immune reaction to the blood thinner heparin that causes clots). It concluded it cannot afford it. The 10-Q now says Cadrenal does "not intend to independently fund or execute late-stage Phase 3 clinical trials for any of our three product candidates" and will instead try to sell, license or co-develop them as a bundle it calls the Cardiac Acute Critical Care franchise:

• CAD-1005, for HIT and for kidney injury after heart surgery. The company says if a Phase 3 is funded, it would support a drug application in 2029.
• Tecarfarin, an oral blood thinner in the same family as warfarin but processed by the body through a different route, aimed at kidney-failure patients, people with heart pumps (LVADs) and, newly, children with Kawasaki disease. On July 8, 2026 the company applied to the FDA for Rare Pediatric Disease Designation in that last group.
• Frunexian, an intravenous blood thinner for heart surgery patients.

So the lower research bill is less about efficiency and more about the company doing less development work while it looks for a partner.

What the headline numbers hide

• Overhead rose sharply from the first quarter. General and administrative costs were $2.63 million in Q2 against $1.74 million in Q1 (the half-year total of $4.38 million minus Q2). Part of that is a one-off: the filing cites severance for the former chief financial officer, agreed in June 2026, plus January pay raises, together adding $0.3 million for the half-year. The company now has an interim CFO. Even so, a business spending $2.6 million a quarter on overhead and $0.7 million on research is mostly paying to stay a listed company.
• The cash burn is real, not an accounting effect. Of the $5.8 million first-half loss, only $0.9 million was non-cash (mainly stock-based pay); cash used in operations was $5.2 million, about $0.87 million a month. Working-capital moves were small: a $0.4 million drop in accrued bills and a $0.2 million rise in prepaid expenses, partly offset by $0.2 million more owed to suppliers.
• The better loss per share is dilution. Net loss shrank 9%, but loss per share shrank 39%, because the loss was spread over 49% more shares. Shares outstanding went from 2.34 million at December 31, 2025 to 3.10 million at June 30, 2026, before the July financing.
• Funding comes from repeated small, expensive raises. In the first half: $2.6 million gross from a warrant holder who exercised early after the exercise price was cut to $4.50 from $16.50 (the company issued 1.14 million new warrants as the sweetener), and $1.46 million gross from selling shares on the market at an average $7.71. Then on June 30, a $3.0 million private placement at $3.1249 per unit that came with warrants for another 1.92 million shares at $3.00. A placement agent took a 7% cash fee on these deals plus its own warrants. The pre-funded warrants alone cover 960,000 shares (469,000 exercised in July), equal to almost a third of the June share count.
• Interest income is fading as the cash pile shrinks: $18,000 in the quarter versus $67,000 a year ago.
• Listing risk. Stockholders' equity fell to $1.8 million at March 31, below Nasdaq's $2.5 million minimum; the company believes the April warrant proceeds restored compliance (equity was $4.1 million at June 30). A new Nasdaq rule requiring at least $5 million in market value of listed shares was approved by the SEC on July 22 and then automatically stayed on July 29; if it takes effect, it allows no cure period.

Takeaway: The narrower loss is a by-product of Cadrenal pulling back from running its own late-stage trials, not progress toward a product. With $2.4 million in the bank at June 30, roughly $0.9 million of cash going out each month, and management's own runway ending in the first quarter of 2027, the story for the next six months is whether a partner or licensing deal arrives before the next round of share dilution.

What to watch next

Management's guidance is limited to the cash runway: $4.2 million in early August is expected to fund operations through the first quarter of 2027, but it "will not be sufficient" to make any of the drugs ready for a trial or to start one. Things to look for in the third-quarter 10-Q, likely around mid-November based on last year's November 10 filing:

• A partnership, licensing or sale announcement for CAD-1005, tecarfarin or the bundle. This is now the stated plan, and without one the company says it may have to scale back or stop operating.
• More share issuance. The 960,000 Series C-1 warrants needed stockholder approval at the annual meeting scheduled for September 24, 2026. At about $0.9 million of monthly burn, the company will likely need to raise again in early 2027 if no partner comes.
• The FDA's answer on Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease, which, if granted, could make the program more attractive to a partner.
• Whether overhead falls back toward the Q1 level of about $1.7 million once the CFO severance is behind it.

On the current trajectory, the drug programs are on hold pending outside money, and the per-share numbers will keep looking better mainly because the share count keeps growing.